Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 17, 2013, Pages 6760-6765

  Krawczyk, Adalbert ^a,b   Arndt, Michaela A E ^b   Grosse Hovest, Ludger ^c   Weichert, Wilko ^b   Giebel, Bernd ^a   Dittmer, Ulf ^a   Hengel, Hartmut ^d   Jäger, Dirk ^b   Schneweis, Karl E ^e   Eis Hübinger, Anna M ^e   Roggendorf, Michael ^a   Krauss, Jürgen ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Acyclovir resistance; Immunocompromised mice; Stem cell transplantation

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HU2C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SPREADING; CONTROLLED STUDY; CROSS REACTION; EFFECTOR CELL; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMORAL IMMUNITY; IMMUNOSURVEILLANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ACYCLOVIR; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; DRUG RESISTANCE, VIRAL; HERPES SIMPLEX; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; NEUTRALIZATION TESTS; SIMPLEXVIRUS; VERO CELLS;

HUMAN HERPESVIRUS 1; MUS; SIMPLEXVIRUS;

EID: 84876868755     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1220019110     Document Type: Article

References (34)

1. Belshe RB, et al.; Herpevac Trial for Women (2012) Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366(1):34-43.
2. Kimberlin DW, et al.; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (2001) Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 108(2):230-238.
3. Berrington WR, et al. (2009) Clinical correlates of herpes simplex virus viremia among hospitalized adults. Clin Infect Dis 49(9):1295-1301.
4. Brooke AE, Eveson JW, Luker J, Oakhill A (1999) Oral presentation of a novel variant of herpes simplex infection in a group of bone marrow transplant patients: A report of five cases. Br J Dermatol 141(2):381-383.
5. Yahav D, et al. (2009) Antiviral prophylaxis in haematological patients: Systematic review and meta-analysis. Eur J Cancer 45(18):3131-3148.
6. Remeijer L, Osterhaus A, Verjans G (2004) Human herpes simplex virus keratitis: The pathogenesis revisited. Ocul Immunol Inflamm 12(4):255-285.
7. Stránská R, et al. (2005) Survey of acyclovir-resistant herpes simplex virus in the Netherlands: Prevalence and characterization. J Clin Virol 32(1):7-18.
8. Danve-Szatanek C, et al. (2004) Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 42(1):242-249.
9. Morfin F, et al. (2004) HSV excretion after bone marrow transplantation: A 4-year survey. J Clin Virol 30(4):341-345.
10. Sauerbrei A, et al. (2011) Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2. Antivir Ther 16(8):1297-1308.
11. Piret J, Boivin G (2011) Resistance of herpes simplex viruses to nucleoside analogues: Mechanisms, prevalence, and management. Antimicrob Agents Chemother 55(2):459-472.
12. Blot N, et al. (2000) Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone Marrow Transplant 26(8):903-905.
13. Darville JM, Ley BE, Roome AP, Foot AB (1998) Acyclovir-resistant herpes simplex virus infections in a bone marrow transplant population. Bone Marrow Transplant 22(6): 587-589.
14. Freeman EE, et al. (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: Systematic review and meta-analysis of longitudinal studies. AIDS 20(1):73-83.
15. Baeten JM, et al. (2008) Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: A randomized, placebo-controlled, cross-over trial. J Infect Dis 198(12):1804-1808.
16. Delany S, et al. (2009) Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: A randomized placebo-controlled trial in South Africa. AIDS 23(4):461-469.
17. Nagot N, et al.; ANRS 1285 Study Group (2007) Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 356(8):790-799.
18. McMahon MA, et al. (2008) The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 283(46):31289-31293.
19. Matamoros T, Kim B, Menéndez-Arias L (2008) Mechanistic insights into the role of Val75 of HIV-1 reverse transcriptase in misinsertion and mispair extension fidelity of DNA synthesis. J Mol Biol 375(5):1234-1248.
20. Krawczyk A, et al. (2011) Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus. J Virol 85(4):1793-1803.
21. Däumer MP, et al. (2011) Characterisation of the epitope for a herpes simplex virus glycoprotein B-specific monoclonal antibody with high protective capacity. Med Microbiol Immunol (Berl) 200(2):85-97.
22. Krauss J, Arndt MA, Martin AC, Liu H, Rybak SM (2003) Specificity grafting of human antibody frameworks selected from a phage display library: Generation of a highly stable humanized anti-CD22 single-chain Fv fragment. Protein Eng 16(10):753-759.
23. Hooks JJ, Burns W, Hayashi K, Geis S, Notkins AL (1976) Viral spread in the presence of neutralizing antibody: Mechanisms of persistence in foamy virus infection. Infect Immun 14(5):1172-1178.
24. Co MS, Deschamps M, Whitley RJ, Queen C (1991) Humanized antibodies for antiviral therapy. Proc Natl Acad Sci USA 88(7):2869-2873.
25. Co MS, et al. (1992) Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 148(4):1149-1154.
26. Almagro JC, Fransson J (2008) Humanization of antibodies. Front Biosci 13:1619-1633.
27. Balzar M, Winter MJ, de Boer CJ, Litvinov SV (1999) The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl) 77(10):699-712.
28. Skartved NJ, et al. (2011) Preclinical pharmacokinetics and safety of Sym004: A syner-gistic antibody mixture directed against epidermal growth factor receptor. Clin Cancer Res 17(18):5962-5972.
29. Bussiere JL, Leach MW, Price KD, Mounho BJ, Lightfoot-Dunn R (2011) Survey results on the use of the tissue cross-reactivity immunohistochemistry assay. Regul Toxicol Pharmacol 59(3):493-502.
30. Chu CF, et al. (2008) Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and-independent mechanisms. J Reprod Immunol 78(1):58-67.
31. Burioni R, Williamson RA, Sanna PP, Bloom FE, Burton DR (1994) Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro. Proc Natl Acad Sci USA 91(1):355-359.
32. Zeitlin L, et al. (1998) A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nat Biotechnol 16(13):1361-1364.
33. Zeitlin L, et al. (1996) Topically applied human recombinant monoclonal IgG1 antibody and its Fab and F(ab')2 fragments protect mice from vaginal transmission of HSV-2. Virology 225(1):213-215.
34. Sanna PP, et al. (1996) Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV. Virology 215(1): 101-106.